Kiniksa Pharmaceuticals Dirección
Dirección controles de criterios 4/4
El CEO de Kiniksa Pharmaceuticals' es Sanj Patel , nombrado en Jul 2015, tiene una permanencia de 8.75 años. compensación anual total es $5.30M, compuesta por 16.3% salario y 83.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.57% de las acciones de la empresa, por valor de $57.06M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 7.3 años, respectivamente.
Información clave
Sanj Patel
Chief Executive Officer (CEO)
US$5.3m
Compensación total
| Porcentaje del salario del CEO | 16.3% |
| Permanencia del CEO | 8.8yrs |
| Participación del CEO | 2.4% |
| Permanencia media de la dirección | 3.4yrs |
| Promedio de permanencia en la Junta Directiva | 7.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25
Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study
Dec 22Dosing underway in Kiniksa Pharma's lumpy skin disease study with vixarelimab
Dec 15Kiniksa Pharma's KPL-404 shows encouraging action in early-stage study
Nov 30Kiniksa's vixarelimab nabs accelerated review in U.S. for a skin disorder
Nov 16Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$5m | US$864k | US$14m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | US$231m |
| Mar 31 2023 | n/a | n/a | US$196m |
| Dec 31 2022 | US$6m | US$835k | US$183m |
| Sep 30 2022 | n/a | n/a | US$143m |
| Jun 30 2022 | n/a | n/a | -US$112m |
| Mar 31 2022 | n/a | n/a | -US$134m |
| Dec 31 2021 | US$7m | US$803k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$175m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$184m |
| Dec 31 2020 | US$5m | US$780k | -US$161m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$123m |
| Mar 31 2020 | n/a | n/a | -US$122m |
| Dec 31 2019 | US$5m | US$780k | -US$162m |
| Sep 30 2019 | n/a | n/a | -US$173m |
| Jun 30 2019 | n/a | n/a | -US$170m |
| Mar 31 2019 | n/a | n/a | -US$153m |
| Dec 31 2018 | US$7m | US$740k | -US$103m |
| Sep 30 2018 | n/a | n/a | -US$93m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$1m | US$700k | -US$65m |
Compensación vs. Mercado: La compensación total ($USD5.30M) de Sanj está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.61M).
Compensación vs. Ingresos: La compensación de Sanj ha sido consistente con los resultados de la empresa en el último año.
CEO
Sanj Patel (54 yo)
8.8yrs
Permanencia
US$5,297,067
Compensación
Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals since July 2015. Before founding Kiniksa Pharmaceuticals in 2015, Mr. Patel founded Synageva BioPharma Corp. in June 2008 a...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman of the Board | 8.8yrs | US$5.30m | 2.39% $ 33.0m | |
| Senior VP & COO | 2.3yrs | US$1.75m | 0.18% $ 2.4m | |
| Senior VP & Chief Medical Officer | 7.8yrs | US$1.79m | 0.067% $ 927.3k | |
| Senior VP & CFO | 3.4yrs | sin datos | 0.026% $ 364.2k | |
| Chief Accounting Officer & Group VP of Finance | 4.3yrs | sin datos | 0.030% $ 413.7k | |
| Senior VP of Technical Operations | 3.3yrs | sin datos | sin datos | |
| Associate Director of Investor Relations | no data | sin datos | sin datos | |
| Senior VP & Chief Compliance Officer | 3.1yrs | sin datos | sin datos | |
| SVP, General Counsel & Secretary | 3.3yrs | sin datos | sin datos | |
| Senior VP & Chief Human Resources Officer | no data | sin datos | sin datos | |
| Executive Vice President of Corporate Affairs | no data | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs | 3.4yrs | sin datos | sin datos |
3.4yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de KNSA se considera experimentado (3.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman of the Board | 8.8yrs | US$5.30m | 2.39% $ 33.0m | |
| Independent Director | 6.3yrs | US$362.66k | 0.0070% $ 97.0k | |
| Lead Independent Director | 8.6yrs | US$411.06k | 0.041% $ 569.4k | |
| Independent Director | 7.4yrs | US$380.36k | 0.0070% $ 97.0k | |
| Independent Director | 8.6yrs | US$372.55k | 0.0070% $ 97.0k | |
| Independent Director | 5.2yrs | US$459.75k | 0.011% $ 150.8k | |
| Independent Director | 3.8yrs | US$365.36k | 0.0070% $ 97.0k | |
| Independent Director | 8.6yrs | US$371.96k | 0.0070% $ 97.0k | |
| Chairman of Scientific Advisory Board | no data | sin datos | 2.08% $ 28.7m | |
| Independent Director | 6.3yrs | US$365.36k | 0.0070% $ 97.0k |
7.4yrs
Permanencia media
55yo
Promedio de edad
Junta con experiencia: La junta directiva de KNSA se considera experimentada (7.3 años de antigüedad promedio).